Scancell announces CFO transition

Summary by AI BETAClose X

Scancell Holdings plc announced a CFO transition with David Schilansky appointed as financial advisor and interim CFO, effective immediately, to ensure continuity as the company advances its iSCIB1+ Phase 3 trial and explores a potential US listing. Current CFO Sath Nirmalananthan will step down on April 24, 2026, and a global search for a permanent CFO is underway. Schilansky brings extensive financing expertise, including experience leading IPOs on Nasdaq and Euronext, and previously served as CEO of Ariceum Therapeutics and Home Biosciences.

Disclaimer*

UK 100

Latest directors dealings